Dr Winston Tan speaks to ecancer at the ASCO Direct Highlights 2022 Miami Symposium about some of the latest updates in bladder, kidney and testes cancer from ASCO 2022.

He first highlights the advances in the treatment of first-line metastatic kidney cancer with the combination of pembrolizumab and axitinib.

Dr Tan then mentions that there is good data on the use of pembrolizumab in the adjuvant setting for high-risk kidney cancer patients.